Vaccination with GM2-KLH-QS21 does not improve outcome of melanomas patients in EORTC study

September 13, 2013, European Organisation for Research and Treatment of Cancer

Results of an EORTC study published in the Journal of Clinical Oncology show that vaccination with GM2/KLH-QS-21 does not benefit patients with stage II melanoma. Vaccination with GM2/KLH-QS-21 stimulates the production of antibodies to the GM2 ganglioside, an antigen expressed by many melanomas. Serological response to GM2 was shown to be a positive prognostic factor in patients with melanoma and was the rationale for this trial.

The idea of treating cancer with a has been around since the first vaccines against infectious disease were developed. The GM2 ganglioside, an antigen expressed in most melanomas but with limited expression in normal tissues, was thought to offer a suitable target for such therapeutic vaccination. Previous studies had shown that serological response against GM2 was a favorable . The five and ten year for patients with having primary tumors with a Breslow thickness greater than 1.5 mm are just of 74% and 61%, respectively, so EORTC trial 18961 was launched to compare vaccination to observation in these patients.

Prof. Alexander M.M. Eggermont of the Institut Gustave Roussy, Villejuif, Paris-Sud, and Université Paris-Sud, Kremlin Bicêtre, France and Coordinator of this study says, "These results clearly indicate that we do not fully comprehend the impact, on the whole, of multiple vaccinations. The effects of such vaccinations might well be detrimental as was clear at the time of the interim analysis that stopped this trial. Now that we have entered a new era in in melanoma with checkpoint inhibitors like anti-CTLA4, and especially with anti-PD1/PDL1, a new opportunity for vaccine development may have arrived."

In this phase III EORTC 18961 trial, 1314 patients with stage II melanoma (primary melanoma thicker than 1.5 mm, T3-4N0M0; AJCC Stage II) were randomized to either vaccination with GM2-KLH-QS21, 657 patients, or observation, 657 patients. The vaccination treatment consisted of subcutaneous injections given once a week during the first month, then once every three months for the first two years, and once every six months during the third year.

Analyses were by intent to treat, and at a median follow-up of 1.8 years the trial was stopped for futility and patients did not receive further vaccinations. For relapse-free survival, the primary endpoint, the hazard ratio (HR) was 1.00 and P = 0.99, and an unfavorable outcome was seen for patients in the vaccination arm compared to the observation arm in terms of overall survival (HR 1.66; P=0.02). Following the IDMC recommendations, all patients in the vaccination arm stopped their treatment.

At final analysis, the median follow-up was 4.2 years. There were 400 relapses, nine deaths without relapse, and a total of 236 deaths. Decreases in both the relapse-free, 1.2%, and overall, 2.1%, survival rates were observed in the vaccination arm at 4 years. For these two endpoints, the estimated HRs were 1.03 and 1.16, respectively.

Toxicity was acceptable; 4.6% of patients went off study because of toxicity.

Explore further: EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST

More information: DOI: 10.1200/JCO.2012.47.9303

Related Stories

EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST

May 29, 2013
Interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST. In the high-risk subgroup, ...

Mortality similar for single and multiple primary melanomas

June 24, 2013
(HealthDay)—Mortality is similar for patients with single primary melanomas (SPMs) and multiple primary melanomas (MPMs), but relative mortality is considerably higher for patients with thicker SPMs versus thicker MPMs, ...

Nonsentinel lymph nodes key factor in melanoma prognosis

August 2, 2013
(HealthDay)—Nonsentinel lymph node (NSLN) positivity is a significant prognostic factor in patients with stage III melanoma, associated with shorter overall and disease-specific survival, according to research published ...

Age-linked variation noted in melanoma management

August 15, 2013
(HealthDay)—Age-related variation is seen in the characteristics and management of melanoma, according to a study published online Aug. 14 in JAMA Dermatology.

Cancer drug improves survival in patients with metastatic melanoma

November 14, 2012
(Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic ...

Study shows radiotherapy and surgery provide regional control for breast cancer patients

June 3, 2013
Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial has shown that both axillary lymph node dissection and axillary radiotherapy provide excellent regional control ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.